AI Engines For more Details: Perplexity Kagi Labs You
Stress Response: Catecholamines are released by the adrenal glands in response to stress, activating the body's "fight or flight" response. They increase heart rate, blood pressure, and blood flow to muscles, preparing the body to respond to a perceived threat or danger. Chronic activation of the stress response and prolonged elevation of catecholamine levels may contribute to the development of stress-related disorders such as anxiety, depression, and cardiovascular disease.
Neurotransmission: In the brain, catecholamines act as neurotransmitters, transmitting signals between nerve cells and regulating mood, attention, motivation, and other cognitive functions. Dopamine, in particular, is involved in the brain's reward system and plays a key role in motivation, pleasure, and reinforcement learning. Dysregulation of dopamine signaling has been implicated in various psychiatric disorders, including schizophrenia, bipolar disorder, and addiction.
Cardiovascular Function: Norepinephrine and epinephrine are important regulators of cardiovascular function. They increase heart rate, contractility, and cardiac output, leading to increased blood flow to the muscles and vital organs during times of stress or physical exertion. However, excessive catecholamine release can lead to hypertension, arrhythmias, and other cardiovascular complications.
Metabolism: Catecholamines influence metabolism by stimulating the breakdown of glycogen into glucose in the liver and promoting lipolysis (breakdown of fats) in adipose tissue. This provides the body with a quick source of energy during times of stress or physical activity. Dysregulation of catecholamine signaling can contribute to metabolic disorders such as obesity, insulin resistance, and diabetes.
Respiratory Function: Catecholamines play a role in regulating respiratory function by increasing the rate and depth of breathing during periods of increased oxygen demand, such as exercise or stress. Epinephrine, in particular, can dilate the airways and improve airflow to the lungs, making it a key component of emergency treatment for severe asthma attacks and anaphylaxis.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Enterococcus durans | Reduces |
| species | Enterococcus faecalis | Reduces |
| species | Enterococcus faecium | Reduces |
| species | Escherichia coli | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.6 | -0.6 | |
| Addison's Disease (hypocortisolism) | 0.5 | -0.5 | |
| ADHD | 0.6 | 0.6 | 0 |
| Allergic Rhinitis (Hay Fever) | 1.7 | 1.2 | 0.42 |
| Allergies | 0.6 | 2.3 | -2.83 |
| Allergy to milk products | 2.4 | 2.4 | 0 |
| Alopecia (Hair Loss) | 0.6 | -0.6 | |
| Alzheimer's disease | 2.4 | 2.4 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.2 | 1.2 | 0 |
| Ankylosing spondylitis | 1.8 | 4.6 | -1.56 |
| Anorexia Nervosa | 0.5 | 0.6 | -0.2 |
| Antiphospholipid syndrome (APS) | 1.2 | -1.2 | |
| Asthma | 1.2 | 2.5 | -1.08 |
| Atherosclerosis | 0.3 | 0.6 | -1 |
| Atrial fibrillation | 1.7 | 1.2 | 0.42 |
| Autism | 4.2 | 4.4 | -0.05 |
| Autoimmune Disease | 0.6 | -0.6 | |
| Barrett esophagus cancer | 0.6 | -0.6 | |
| benign prostatic hyperplasia | 0.6 | -0.6 | |
| Biofilm | 0.3 | 1.7 | -4.67 |
| Bipolar Disorder | 2.9 | -2.9 | |
| Brain Trauma | 1.9 | -1.9 | |
| Breast Cancer | 0.6 | -0.6 | |
| Cancer (General) | 1 | -1 | |
| Carcinoma | 1.2 | -1.2 | |
| Celiac Disease | 1.1 | 1.9 | -0.73 |
| Cerebral Palsy | 0.5 | 0.5 | |
| Chronic Fatigue Syndrome | 0.5 | 2.3 | -3.6 |
| Chronic Kidney Disease | 2.4 | -2.4 | |
| Chronic Lyme | 0.6 | -0.6 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 1.7 | -1.83 |
| Chronic Urticaria (Hives) | 1.8 | -1.8 | |
| Coagulation / Micro clot triggering bacteria | 2.2 | -2.2 | |
| Cognitive Function | 0.6 | -0.6 | |
| Colorectal Cancer | 1.7 | 4.1 | -1.41 |
| Constipation | 2.3 | -2.3 | |
| Coronary artery disease | 0.5 | 1.8 | -2.6 |
| COVID-19 | 3.1 | 4.6 | -0.48 |
| Crohn's Disease | 1.2 | 4 | -2.33 |
| Cushing's Syndrome (hypercortisolism) | 0.6 | -0.6 | |
| cystic fibrosis | 0.5 | 2.8 | -4.6 |
| d-lactic acidosis (one form of brain fog) | 0.6 | -0.6 | |
| deep vein thrombosis | 2.9 | -2.9 | |
| Denture Wearers Oral Shifts | 0.8 | 0.8 | |
| Depression | 3 | 4.2 | -0.4 |
| Dermatomyositis | 0.6 | -0.6 | |
| Eczema | 0.5 | 1.2 | -1.4 |
| Endometriosis | 1.1 | 3 | -1.73 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 0.5 | 2.4 | -3.8 |
| erectile dysfunction | 0.6 | -0.6 | |
| Functional constipation / chronic idiopathic constipation | 0.6 | 3.5 | -4.83 |
| gallstone disease (gsd) | 0.2 | 2.2 | -10 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | -0.6 | |
| Generalized anxiety disorder | 1 | 1.9 | -0.9 |
| Gout | 1.1 | 0.6 | 0.83 |
| Graves' disease | 0.6 | 0.6 | |
| Gulf War Syndrome | 1.2 | -1.2 | |
| Hashimoto's thyroiditis | 1.1 | 0.5 | 1.2 |
| Heart Failure | 0.5 | 3 | -5 |
| High Histamine/low DAO | 0.3 | 3.6 | -11 |
| hypercholesterolemia (High Cholesterol) | 1.2 | -1.2 | |
| hyperglycemia | 1.2 | -1.2 | |
| Hyperlipidemia (High Blood Fats) | 1.1 | 2.3 | -1.09 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 1.4 | 2.9 | -1.07 |
| Hypothyroidism | 0.6 | 0.6 | |
| Hypoxia | 2.2 | -2.2 | |
| IgA nephropathy (IgAN) | 1.1 | -1.1 | |
| Inflammatory Bowel Disease | 2.6 | 3.9 | -0.5 |
| Insomnia | 0.6 | 0.6 | 0 |
| Intelligence | 0.6 | -0.6 | |
| Intracranial aneurysms | 0 | 0.6 | 0 |
| Irritable Bowel Syndrome | 2.3 | 5.9 | -1.57 |
| ischemic stroke | 0.6 | 1.1 | -0.83 |
| Liver Cirrhosis | 1.7 | 4.1 | -1.41 |
| Long COVID | 2.3 | 2.9 | -0.26 |
| Lung Cancer | 0.6 | -0.6 | |
| Lymphoma | 0.6 | -0.6 | |
| Mast Cell Issues / mastitis | 0.6 | 2.4 | -3 |
| ME/CFS with IBS | 0.5 | 0.5 | 0 |
| ME/CFS without IBS | 0.5 | 0.5 | 0 |
| Metabolic Syndrome | 2 | 5.2 | -1.6 |
| Mood Disorders | 3.7 | 4.6 | -0.24 |
| Multiple Sclerosis | 1.8 | -1.8 | |
| myasthenia gravis | 1.1 | 1 | 0.1 |
| Neuropathy (all types) | 1.2 | 0.6 | 1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | -0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 5.2 | -7.67 |
| NonCeliac Gluten Sensitivity | 1.2 | -1.2 | |
| Obesity | 1.7 | 5.3 | -2.12 |
| obsessive-compulsive disorder | 0.5 | 4 | -7 |
| Osteoarthritis | 1 | -1 | |
| Osteoporosis | 1.8 | -1.8 | |
| pancreatic cancer | 0.6 | 0.6 | 0 |
| Parkinson's Disease | 2.9 | 5.8 | -1 |
| Polycystic ovary syndrome | 0.5 | 2.3 | -3.6 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| primary biliary cholangitis | 0.5 | 0.6 | -0.2 |
| Primary sclerosing cholangitis | 0.8 | 1.6 | -1 |
| Psoriasis | 1.7 | 0.6 | 1.83 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.7 | 5.1 | -2 |
| Rosacea | 0.6 | 0.6 | |
| Schizophrenia | 1.3 | 3.4 | -1.62 |
| scoliosis | 1.2 | -1.2 | |
| sensorineural hearing loss | 0.5 | -0.5 | |
| Sjögren syndrome | 0.6 | 0.6 | 0 |
| Sleep Apnea | 1.1 | -1.1 | |
| Slow gastric motility / Gastroparesis | 1.2 | -1.2 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 2.5 | -1.78 |
| Stress / posttraumatic stress disorder | 1.1 | 2.3 | -1.09 |
| Systemic Lupus Erythematosus | 2.3 | 3 | -0.3 |
| Type 1 Diabetes | 1.1 | 2.4 | -1.18 |
| Type 2 Diabetes | 2.8 | 4.6 | -0.64 |
| Ulcerative colitis | 2.7 | 4 | -0.48 |
| Unhealthy Ageing | 0.5 | 0.6 | -0.2 |
| Vitiligo | 0.6 | -0.6 |
